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Abstract
Background: Setting of graded levels of a protein for in vivo studies by controlled gene expression
has inconveniences, and we here explore the use of the t-degron technique instead.
Results: In a yeast t-degron (ubiquitin-argDHFRts)- phosphoglycerate mutase (GPM1) fusion strain,
increasing periods of exposure to the non-permissive temperature 37°C, even in the presence of
cycloheximide, gave decreasing function, as assessed at 23°C in vivo by glucose metabolism and
confirmed by immunoblot.
Conclusion: An ideal system would set a range of lower levels of a protein, do so without
compensating protein synthesis, and give stable activity for in vitro comparisons. Although the first
two aims appear obtainable, the third was not in this example of the application, limiting its uses
for some but not all purposes.
Background
Modeling of metabolism – the matching of enzyme and
physiology – is a familiar theme in biochemistry and can
be an exacting exercise even for the long studied glycolytic
pathway [1,2]. A contribution of genetics would be to sup-
ply strains with altered levels of a particular enzyme as de-
sired. Knock-outs are inappropriate for quantitative study
of the reaction itself, and although increases are readily
got with cloned genes on multicopy vectors, with many
enzymes in apparent excess lowered levels are of more in-
terest. In an earlier report we have assessed glucose metab-
olism in yeast gcr mutants where levels of several
glycolytic enzymes are decreased [3] and a logical next
step was to arrange their individual decreases.
The usual way to decrease an enzyme level is to change ex-
pression of the gene by promoter alteration or regulation.
Apart from the practicalities, such methods have the limi-
tation that since the adjustment is a process that must oc-
cur during growth, compensating enzymes, known or not,
can also change in level. So for some purposes conditional
activity is preferred over conditional expression. Rather
than a temperature sensitive enzyme, which is not suited
for graded levels of activity, we here report application of
the td-mutant technique of Dohmer et al. [4], where the
temperature-inactivated degron, a ts-version of mouse-di-
hydrofolate reductase carrying an N-terminal arginine res-
idue, is placed between ubiquitin and a protein of interest
(POI), i.e., a Ub-td-POI gene construction, giving a td-POI
protein fusion (the ubiquitin is postranslationally
cleaved) which is stable at 23°C but degraded at 37°C.
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The method has been fairly widely employed to knock out
a POI (e.g., by an hour's treatment at 37°C), and it is
known from in vitro assessment that intermediate times of
treatment can give intermediate levels of activity [5,6]. For
cell processes which do not require protein synthesis –
and glucose metabolism is one of them – it is possible that
in vivo studies with intermediate activity levels could
therefore be accomplished by restoration to 23°C in a
non-growing condition, preventing further degradation or
replenishment of the activity, with the functional assess-
ment being done at the lower temperature. Furthermore,
if the 37°C inactivation process did not require protein
synthesis either, the inactivation could also be done in the
non-growing condition and thus nominally allow the ad-
justment of enzyme levels without compensating induc-
tion of other proteins.
We test with partial success those two possibilities, using
the glycolytic enzyme phosphoglycerate mutase (gene
GPM1), a step whose single knock out greatly impairs glu-
cose growth and metabolism and which is also particular-
ly affected by gcr mutations.
Results and Discussion
As shown in Table 1, the expected td-Gpm mutant pheno-
type was obtained, i.e., major growth impairment at 37°C
and restoration by ubr1. Depending on the test, growth of
the mutant was somewhat impaired at 30°C, as shown
best by the extra sensitivity to the respiration inhibitor an-
timycin A. Growth was marginally abnormal even at the
nominally permissive 23°C.
Glucose metabolism, at 23°C, in resting cells [3,7] was
first assessed with cells grown at 23°C but pretreated in
growth medium for an additional period of 30 min at
37°C (or, control, 23°C). As shown in Fig. 1, from both
temperatures the wild type strain showed similar glucose
metabolism and the usual low glycerate-3-P concentra-
tion. By contrast, lower panels, the 37°C-pretreated mu-
tant suspension was considerably lowered in its rate of
glucose metabolism and glycerate-3-P was accumulated to
high level, as in a phosphoglycerate mutase mutant [3];
the control cells not exposed to 37°C showed slightly ele-
vated levels of this metabolite. The decrease in glucose
flux, v, in the test situation of non-growing cells at 23°C,
depended on time of previous exposure to 37°C, with,
e.g., values of 0.76 (no exposure to 37°C), 0.24 (30 min
exposure), 0.09 (60 min) and 0.03 (90 min). Thus it ap-
pears that inactivation of the reaction in vivo was stopped
by restoration to the lower temperature.
To get graded levels of a protein by timed exposure to the
higher temperature in a condition when new proteins
were not made, the simplest protocol would be for the
37°C treatment to use the same non-growing condition as
employed anyway for assessing metabolism – a buffer
containing cycloheximide – before returning to the lower
temperature for the functional testing. But this failed: a v
value of 0.49 of an untreated suspension of the mutant
was about the same, 0.41, after a 90 min pretreatment at
37°C, perhaps because inactivation by ubiquitination and
proteosome function needs ATP, which is depleted in star-
vation. Indeed, when glucose was also present during the
pretreatment of the inhibited cells at 37°C, then the de-
sired range of glucose fluxes was obtained in the subse-
quent test at 23°C, Fig. 2, with prominent glycerate-3-P
accumulation.
Unfortunately, in vitro assay of phosphoglycerate mutase
activity gave variable levels in the range of 0–5% even for
the mutant not exposed to 37°C – in spite of its almost
normal glucose metabolism – and similar marginal values
Table 1: Growth. Wild type, td-Gpm mutant, and ubr1-suppressed mutant were assessed at three temperatures in enriched or minimal 
medium with 1% glucose.
Wild type td-Pgm Mutant ubr1-Suppressed Mutant
24°C3 0 °C3 7 °C2 4 °C3 0 °C3 7 °C2 4 °C3 0 °C3 7 °C
Medium R col., 3d mm 1.7 2.8 3 1.4 2.2 0.1 1.5 2.1 3.2
"M u h -1 ND 0.39 0.39 ND 0.37 0.07 ND 0.41 0.41
"v glucose umol*h-1* ODU-1 ND 2.7 2.9 ND 1.4 ND ND 2.7 2.7
Medium M col., 3d 1.1 1.6 1 0.8 0.7 <0.1 1 1.5 1.1
" (+ Ant A) col., 3d 0.3 0.9 1.1 0.2 <0.1 <0.1 0.3 1 0.8
" (+ Ant A) col., 5d 1 1.7 1.9 0.7 <0.1 <0.1 1 1.5 1.3
ND, not done. Col., average colony size in mm at the indicated time of incubation, using plates spread with not more than 50 cfu. vglucose is the rate 
of glucose metabolism. Ant A, antimycin A, 2 ug/ml.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/13
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Figure 1
Glucose metabolism at 23°C after pretreatment in growth medium at 37°C. The control cultures, left hand panels, were simi-
larly handled, but at 23°C. Left hand axes are for glucose or ethanol, mM in medium; right hand axes for fructose-1,6-P2 (Fru-
1,6-P2) and glycerate-3-P (Gta-3-P), mM in cells.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/13
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were also found with the ubr1-suppressed mutant. These
results likely reflect in vitro lability of the td-Gpm fusion
protein, which therefore had to be measured as antigen.
As shown by immunoblot (Fig. 3), the strains with td-
Gpm substituted for normal Gpm only showed the ex-
pected larger fusion protein. For the cultures not exposed
to 37°C (left hand four lanes), in line with the signs of
some growth impairment even at permissive temperature,
the signal in the mutant was much lower than wild type
(ca. 10%, by comparison of two-fold dilutions); it was
somewhat higher in the ubr1-suppressed mutant. As ex-
pected, a 37°C preincubation (right hand four lanes) had
little effect in wild type but substantially reduced the mu-
tant signal – unless the strain also carried ubr1.
Thus, both starting expectations were met: intermediate
levels of a POI could be provided for in vivo study and the
adjustment even done in non-growing conditions. How-
ever, the method has several disadvantages at present. The
clearly low level of fusion protein even in the ubr1-sup-
pressed mutant grown at 23°C suggests low expression. D.
Finley has pointed out that the new NdeI site (see Meth-
ods) might have impaired translation initiation; this
problem could be avoided by a different construction. It
may also be that although the GPM1 promoter is very
strong, other disadvantages of the fusion, such as non-ide-
al codon usage in the degron might require compensation
by overexpression. We used, but did not have to, the nor-
mal promoter and normal chromosomal context. By con-
trast, most genes are expressed at far lower level than
GPM1 and most td work has used the CUP1 promoter.
One attraction of t-degron methods is portability, the
same construction being effective with many POI's – as
seen in its uses for functional knockout by temperature,
the large N-terminal td extension being acceptable for
many proteins. The same generality would be anticipated
to the use suggested here to setting of intermediate levels.
However, in general quantitation of function of fusion
proteins has been limited, and it may be that even with
improved expression the method will not be widely useful
for our original aim, which was to obtain different levels
of stable activity characterizable in vitro for purposes of
modeling. But those properties are not needed in all appli-
cations, and many proteins are not assayed by their activ-
ity in vitro anyway.
Regarding phosphoglycerate mutase, the present results
suggest that a level in the 10% range is adequate. That val-
ue would be a maximum, since the specific activity of the
fusion protein is not known. A strain with mutant Pgm
and 0.7% of wild type activity level grew in YEPD medium
at 1/5 the wild type rate [8], and a strain with GPM1 under
pGAL control and 3% of normal activity grew adequately
on galactose [3]. These numbers emphasize the need for
methods to set enzyme levels, and suggest that at least for
phosphoglycerate mutase a low range will be of interest.
Conclusion
This report is a first step in adapting the portable t-degron
system to use in setting up of intermediate enzyme activi-
ties rather than knock-out. The most useful system would
allow setting of a range of lower levels of a protein, do so
without compensating protein synthesis, and give stable
Figure 2
Glucose metabolism in the mutant at 23°C after pretreatment at 37°C in the non-growing condition with glucose. Other
details are as in Fig. 1.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/13
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activity for in vitro comparisons. Although the first two
aims appear obtainable, the third one was not in this ex-
ample of the application, which limits its uses for some
purposes.
Methods
The "wild type" strain is HD162-5A [9] and the "td-Gpm
mutant" is a derivative, DFY758, with Ub-td inserted at
the initiation codon of the phosphoglycerate mutase gene
GPM1 in normal chromosomal context. The construction
was (i), to make a plasmid with Ub-td flanked by NdeI
sites (so that the same fragment could be inserted at any
suitably modified ATG). Plasmid pPW66R (from R Do-
hman [4]) carries pCUP1-Ub-ArgDHFRts – ha-CDC281–
95 in YIpRS306, and a NdeI-bounded 897 bp fragment
(from ATG of Ub to ATG of CDC28) was obtained by PCR
using (5' to 3') primers CTTTAACTAATAGCATATGCA-
GATTTTCG and TTCACCGCTCATATGCCCGGAAGCTT
and cloned into the NdeI site of pUC19. (ii) The EcoR1 in-
sert from GPM1/YEp352 (from H Uemura), a 2076 frag-
ment with GPM1(YKL152C), 737 bp, flanked by 1001 bp
5' and 346 bp 3', was subcloned into pUC19 with its NdeI
site removed by fill-in. An NdeI site was then introduced
at the initiation codon of GPM1, using two back-to-back
primers at bp12 of the ORF, 5' to 3', AACTTTGGCATAT-
GTGTAATATGTGT and AGTTTTAGTTAGACACGGTCAAT
and PCR followed by ligation, confirmed by sequencing,
and the NdeI Ub-td fragment was introduced at the new
site and its orientation and junction likewise confirmed.
Its 2792 bp EcoRI [1001 bp 5'/ Ub-td-GPM1/157 bp 3']
SalI fragment was placed into YipRS306, cut with BglI (bp
485 of GPMI) and transformed into the wild type strain
with Ura+ selection on glucose at 30°C. Candidate inte-
grants were grown in enriched medium with glucose at
23°C, and strain DFY758 was identified as an FOAr (Ura-
) segregant which was ts in growth on glucose. Ubr1p is a
recognition component for degradation of td constructs,
and a td-Gpm1 ubr1 strain (DFY760) contains ubr1::HIS3
introduced by transplacement from pJDubrdelta4-b
(from R.J. Dohmen); its growth was not temperature sen-
sitive. For comparison, ubr1 was also placed in the wild
type UBR1 background (strain DFY655).
Growth and analysis of glucose metabolism was as de-
scribed [3,7]. Enriched medium R (buffer B61, 0.4% Difco
yeast extract, 1% Difco tryptone) supplemented with 1%
glucose was used throughout, except for the minimal me-
dium M (buffer B61 and 0.67% Difco yeast nitrogen base
plus needed supplements) entries in Table 1. Incubations
with resting cells, at 23°C, used suspensions at 50–150
ODU580/ml in buffer B61 containing cycloheximide (10
ug/ml) and antimycin A (2 ug/ml). Rates of glucose me-
tabolism, v, are given as umoles/h/ODU, and cytoplasmic
concentrations of metabolites were normalized to ODU
[3]. Pretreatment at 37°C was (Fig. 1) in growth medium
or (Fig. 2) in the resting cell condition and was followed
by washing and the usual incubation with glucose at the
lower temperature. For antibody, S. cerevisiae phos-
phoglycerate mutase (from L. Gilmore [8]) was obtained
(Covance Research Products Inc.) by the regime of 250 ug
in Freund's Complete Adjuvant, followed at 3 and 6 weeks
by 125 ug in Freund's Incomplete Adjuvant and with
bleeds at 7 and 9 weeks; the antiserum was preabsorbed
with a crude extract from a pgm1 mutant. For the immu-
noblot blot of Fig. 3, cells grown at 23°C were preincubat-
ed 70 min at 23°C or 37°C in buffer 61 with
cycloheximide (10 ug/ml) and 1% glucose, and then
washed and reincubated 1 h, both at 23°C, in the resting
cell buffer with 1% glucose. The cells were then resus-
pended at 100 ODU/ml in SDS gel sample buffer contain-
ing 100 mM DTT, heated 5 min at 95°C and treated 50 sec.
with glass beads, and 10 uL amounts used in SDS-PAGE,
employing Biorad broad range prestained standards. Blot-
ting was to Millipore Immobilon P transfer membrane,
blocking with condensed milk, and after incubation with
the anti-Gpm antiserum detection by the Amersham ECL
method with HRP-labeled goat anti-rabbit antibody.
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